Status:
COMPLETED
A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Advanced Solid Tumors
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
Eligibility Criteria
Inclusion
- Confirmed advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy.
- Adequate coagulation, liver and renal function.
- Candidate for DCE-MRI evaluation.
- ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.
Exclusion
- Evidence of bleeding problems.
- Uncontrolled hypertension.
- Certain gastrointestinal problems including fistula and abscess.
- Patients with primary brain cancer.
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00879554
Start Date
February 1 2007
End Date
November 1 2010
Last Update
December 13 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85258
2
Pfizer Investigational Site
Santa Monica, California, United States, 90404
3
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111